“杭州服务”让创新药落地速度“跑”起来

Core Insights - Hangzhou's biopharmaceutical industry is experiencing significant growth, with the approval of the innovative drug "维培那肽注射液" (brand name "派达康") marking the fifth first-class innovative drug approved in the city this year [1] - The city accounts for 75% of the first-class innovative drug applications in the province, leading in several key metrics [1] Group 1: Drug Development and Innovation - The innovative drug "维培那肽" utilizes a PEGylation technology that effectively resists DPP-4 enzyme degradation and significantly reduces renal clearance rates, ensuring high bioactivity and prolonged exposure time in clinical treatments [1] - During the "14th Five-Year Plan" period, 12 innovative drug specifications were approved in Hangzhou, representing 54.5% of the province's total [1] - By the third quarter of 2025, the province had 647 new drug applications, with Hangzhou contributing 262 applications, or 40.5% of the total [1] Group 2: Industry Support and Services - Hangzhou has 133 pharmaceutical manufacturing companies and approximately 103 clinical trial and new drug application institutions, with nearly 300 innovative drug clinical projects approved [2] - The city has implemented a "one-stop" service model to reduce operational and communication costs for enterprises, including personalized guidance and dynamic monitoring of innovative product demands [2] - The local market supervision department has proactively assisted companies by addressing issues and facilitating access to special funds, thereby alleviating financial pressures [2]